vs
null（SWIM）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
TransMedics Group, Inc.の直近四半期売上が大きい（$160.8M vs $100.0M、nullの約1.6倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs -7.0%、差は72.6%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 14.5%）。TransMedics Group, Inc.の直近四半期フリーキャッシュフローが多い（$19.0M vs $14.1M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs -4.9%）
米国発祥の多国籍法律事務所で、1934年にカリフォルニア州ロサンゼルスで設立されました。訴訟業務、企業法務、規制関連法務の分野で豊富な実績を持ち、世界的にも影响力のある総合法律事務所として知られています。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
SWIM vs TMDX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $100.0M | $160.8M |
| 純利益 | $-7.0M | $105.4M |
| 粗利率 | 28.0% | 58.1% |
| 営業利益率 | -10.7% | 13.2% |
| 純利益率 | -7.0% | 65.6% |
| 売上前年比 | 14.5% | 32.2% |
| 純利益前年比 | 76.0% | 1436.9% |
| EPS（希薄化後） | $-0.06 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $100.0M | $160.8M | ||
| Q3 25 | $161.9M | $143.8M | ||
| Q2 25 | $172.6M | $157.4M | ||
| Q1 25 | $111.4M | $143.5M | ||
| Q4 24 | $87.3M | $121.6M | ||
| Q3 24 | $150.5M | $108.8M | ||
| Q2 24 | $160.1M | $114.3M | ||
| Q1 24 | $110.6M | $96.8M |
| Q4 25 | $-7.0M | $105.4M | ||
| Q3 25 | $8.1M | $24.3M | ||
| Q2 25 | $16.0M | $34.9M | ||
| Q1 25 | $-6.0M | $25.7M | ||
| Q4 24 | $-29.2M | $6.9M | ||
| Q3 24 | $5.9M | $4.2M | ||
| Q2 24 | $13.3M | $12.2M | ||
| Q1 24 | $-7.9M | $12.2M |
| Q4 25 | 28.0% | 58.1% | ||
| Q3 25 | 35.4% | 58.8% | ||
| Q2 25 | 37.1% | 61.4% | ||
| Q1 25 | 29.5% | 61.5% | ||
| Q4 24 | 24.6% | 59.2% | ||
| Q3 24 | 32.4% | 55.9% | ||
| Q2 24 | 33.1% | 60.6% | ||
| Q1 24 | 27.7% | 61.9% |
| Q4 25 | -10.7% | 13.2% | ||
| Q3 25 | 13.3% | 16.2% | ||
| Q2 25 | 14.3% | 23.2% | ||
| Q1 25 | -4.4% | 19.1% | ||
| Q4 24 | -14.9% | 7.1% | ||
| Q3 24 | 8.9% | 3.6% | ||
| Q2 24 | 12.5% | 10.9% | ||
| Q1 24 | -1.9% | 12.8% |
| Q4 25 | -7.0% | 65.6% | ||
| Q3 25 | 5.0% | 16.9% | ||
| Q2 25 | 9.3% | 22.2% | ||
| Q1 25 | -5.4% | 17.9% | ||
| Q4 24 | -33.4% | 5.6% | ||
| Q3 24 | 3.9% | 3.9% | ||
| Q2 24 | 8.3% | 10.7% | ||
| Q1 24 | -7.1% | 12.6% |
| Q4 25 | $-0.06 | $2.59 | ||
| Q3 25 | $0.07 | $0.66 | ||
| Q2 25 | $0.13 | $0.92 | ||
| Q1 25 | $-0.05 | $0.70 | ||
| Q4 24 | $-0.24 | $0.19 | ||
| Q3 24 | $0.05 | $0.12 | ||
| Q2 24 | $0.11 | $0.35 | ||
| Q1 24 | $-0.07 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | — | — |
| 総負債低いほど良い | $279.8M | — |
| 株主資本純資産 | $405.9M | $473.1M |
| 総資産 | $823.2M | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.69× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $330.1M | ||
| Q2 24 | — | $362.8M | ||
| Q1 24 | — | $350.2M |
| Q4 25 | $279.8M | — | ||
| Q3 25 | $281.1M | — | ||
| Q2 25 | $281.5M | — | ||
| Q1 25 | $306.9M | — | ||
| Q4 24 | $281.5M | — | ||
| Q3 24 | $282.8M | — | ||
| Q2 24 | $282.4M | — | ||
| Q1 24 | $282.8M | — |
| Q4 25 | $405.9M | $473.1M | ||
| Q3 25 | $408.4M | $355.2M | ||
| Q2 25 | $398.4M | $318.1M | ||
| Q1 25 | $381.1M | $266.3M | ||
| Q4 24 | $387.2M | $228.6M | ||
| Q3 24 | $416.6M | $209.9M | ||
| Q2 24 | $408.1M | $189.9M | ||
| Q1 24 | $391.8M | $159.5M |
| Q4 25 | $823.2M | $1.1B | ||
| Q3 25 | $844.4M | $946.0M | ||
| Q2 25 | $822.1M | $890.5M | ||
| Q1 25 | $824.6M | $837.5M | ||
| Q4 24 | $794.2M | $804.1M | ||
| Q3 24 | $853.4M | $785.6M | ||
| Q2 24 | $830.0M | $758.6M | ||
| Q1 24 | $808.6M | $723.8M |
| Q4 25 | 0.69× | — | ||
| Q3 25 | 0.69× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.81× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 0.72× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $23.3M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $14.1M | $19.0M |
| FCFマージンFCF / 売上 | 14.1% | 11.8% |
| 設備投資強度設備投資 / 売上 | 9.2% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | — | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $38.0M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $23.3M | $34.5M | ||
| Q3 25 | $51.0M | $69.6M | ||
| Q2 25 | $36.0M | $91.6M | ||
| Q1 25 | $-46.9M | $-2.9M | ||
| Q4 24 | $6.2M | $19.7M | ||
| Q3 24 | $37.2M | $6.9M | ||
| Q2 24 | $52.4M | $25.7M | ||
| Q1 24 | $-34.5M | $-3.4M |
| Q4 25 | $14.1M | $19.0M | ||
| Q3 25 | $45.2M | $61.9M | ||
| Q2 25 | $29.1M | $82.5M | ||
| Q1 25 | $-50.3M | $-29.9M | ||
| Q4 24 | $-98.0K | $6.1M | ||
| Q3 24 | $33.2M | $-41.3M | ||
| Q2 24 | $47.9M | $2.0M | ||
| Q1 24 | $-39.9M | $-47.6M |
| Q4 25 | 14.1% | 11.8% | ||
| Q3 25 | 27.9% | 43.1% | ||
| Q2 25 | 16.8% | 52.4% | ||
| Q1 25 | -45.2% | -20.8% | ||
| Q4 24 | -0.1% | 5.0% | ||
| Q3 24 | 22.1% | -38.0% | ||
| Q2 24 | 29.9% | 1.7% | ||
| Q1 24 | -36.0% | -49.2% |
| Q4 25 | 9.2% | 9.7% | ||
| Q3 25 | 3.6% | 5.3% | ||
| Q2 25 | 4.0% | 5.8% | ||
| Q1 25 | 3.1% | 18.8% | ||
| Q4 24 | 7.2% | 11.2% | ||
| Q3 24 | 2.7% | 44.3% | ||
| Q2 24 | 2.8% | 20.8% | ||
| Q1 24 | 4.8% | 45.6% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | 6.29× | 2.86× | ||
| Q2 25 | 2.25× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | — | 2.87× | ||
| Q3 24 | 6.32× | 1.63× | ||
| Q2 24 | 3.95× | 2.11× | ||
| Q1 24 | — | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
SWIM
| In Ground Swimming Pools | $50.2M | 50% |
| Covers | $37.0M | 37% |
| Liners | $12.7M | 13% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
